Fig. 4
From: EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells
EZH2 inhibitors enhance gefitinib-induced apoptosis of primary gefitinib-resistant A549 and H1299 cell lines. a-b Apoptosis was analyzed by flow cytometry analysis after 48 h exposure to GSK343, DZNep, gefitinib, GSK343 + gefitinib, and D + g. Data are presented as mean ± standard deviation (n = 3 independent experiments).* P < 0.05, ** P < 0.01, vs. the gefitinib alone-treated group. c The effects of GSK343, DZNep, and gefitinib on Bcl-2, Bax, caspase-3, cleaved caspase-3 and PARP,p62 and LC3 protein levels in A549 and H1299 cells were evaluated by western blotting